Roche has advised us that the tocilizumab shortage has now been resolved. Supply of intravenous (IV) and subcutaneous (SC) tocilizumab has returned to normal pre-pandemic levels.
- New patients may be initiated on any of the tocilizumab presentations (IV or SC).
- Patients may resume or switch back to any of the tocilizumab presentations (IV or SC) as deemed appropriate by their specialist.
- The Serious Scarcity Substitution Instrument (SSSI) and the TGA shortage notification for tocilizumab SC formulations expired on 30 April 2022.
Please refer to the TGA website for further details. More information is available on the ARA website for ARA Members, and on the Arthritis Australia website for patients and consumers.